Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase NA 4Phase 2 3Phase 4 2Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 2Cancer Pain 2Pain 1Opioid-Related Disorders 1Lymphoma, Follicular 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × Morphine × Clear all
NCT02078089 2017-01-31

Oxcarbazepine Plus Morphine in Patients With Refractory Cancer Pain

Indiana University

Phase 1 Terminated
1 enrolled

Cancer Pain, Neoplasms

NCT00125684 2012-01-19

Bioavailability and Effectiveness of Transdermally Administered Morphine

AHS Cancer Control Alberta

Phase 1 Completed
6 enrolled

Cancer Pain, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡